标题
New and Emerging Systemic Treatments for Atopic Dermatitis
作者
关键词
-
出版物
DRUGS
Volume 80, Issue 11, Pages 1041-1052
出版商
Springer Science and Business Media LLC
发表日期
2020-06-09
DOI
10.1007/s40265-020-01335-7
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Baricitinib in patients with moderate‐to‐severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials
- (2020) E.L. Simpson et al. BRITISH JOURNAL OF DERMATOLOGY
- Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis
- (2020) Emma Guttman-Yassky et al. JAMA Dermatology
- Revisiting Therapies for Atopic Dermatitis that Failed Clinical Trials
- (2020) Gaurav Agnihotri et al. CLINICAL DRUG INVESTIGATION
- Atopic dermatitis endotypes and implications for targeted therapeutics
- (2019) Tali Czarnowicki et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Atopic dermatitis is an IL-13 dominant disease with greater molecular heterogeneity compared to psoriasis
- (2019) Lam C. Tsoi et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis
- (2019) Emma Guttman-Yassky et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Real‐world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: A single‐centre retrospective study
- (2019) H. Uchida et al. BRITISH JOURNAL OF DERMATOLOGY
- Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials
- (2019) J.I. Silverberg et al. BRITISH JOURNAL OF DERMATOLOGY
- Conjunctivitis in dupilumab clinical trials
- (2019) B. Akinlade et al. BRITISH JOURNAL OF DERMATOLOGY
- Real‐world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records
- (2019) Candice Wang et al. INTERNATIONAL JOURNAL OF DERMATOLOGY
- Dupilumab shows long-term safety and efficacy in moderate-to-severe atopic dermatitis patients enrolled in a phase 3 open-label extension study
- (2019) Mette Deleuran et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Upadacitinib versus Placebo or Adalimumab in Patients with Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase 3, Double‐Blind, Randomized Controlled Trial
- (2019) Roy Fleischmann et al. Arthritis & Rheumatology
- Dupilumab-induced ocular surface disease (DIOSD) in patients with atopic dermatitis: clinical presentation, risk factors for development and outcomes of treatment with tacrolimus ointment
- (2019) Yoav Nahum et al. BRITISH JOURNAL OF OPHTHALMOLOGY
- Mechanisms of Dupilumab
- (2019) Hani Harb et al. CLINICAL AND EXPERIMENTAL ALLERGY
- Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial
- (2019) Robert Bissonnette et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus
- (2019) Jonathan I. Silverberg et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase II a open‐label trial and subsequent phase III open‐label extension
- (2019) M.J. Cork et al. BRITISH JOURNAL OF DERMATOLOGY
- The IL ‐13– OVOL 1– FLG axis in atopic dermatitis
- (2019) Kazuhisa Furue et al. IMMUNOLOGY
- Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial
- (2019) Emma Guttman-Yassky et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis
- (2019) Eric L. Simpson et al. JAMA Dermatology
- Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis
- (2019) Melinda J. Gooderham et al. JAMA Dermatology
- Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial
- (2019) Amy S. Paller et al. AMERICAN JOURNAL OF CLINICAL DERMATOLOGY
- Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting
- (2019) Hideaki Uchida et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t
- (2018) M. de Bruin-Weller et al. BRITISH JOURNAL OF DERMATOLOGY
- A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers
- (2018) Paul Baverel et al. Drug Metabolism and Pharmacokinetics
- Nemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study
- (2018) Kenji Kabashima et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Treatment of atopic dermatitis with tralokinumab, an anti–IL-13 mAb
- (2018) Andreas Wollenberg et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Baricitinib in adult patients with moderate-to-severe atopic dermatitis: a phase 2 parallel, double-blinded, randomized placebo-controlled multiple-dose study
- (2018) Emma Guttman-Yassky et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)
- (2018) Eric L. Simpson et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Dupilumab: short-term effectiveness and security in real clinical practice - A retrospective multicentric study
- (2018) R. Ruiz-Villaverde et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Alopecia Areata in Severe Atopic Dermatitis Treated With Dupilumab
- (2018) B Barroso-García et al. JOURNAL OF INVESTIGATIONAL ALLERGOLOGY AND CLINICAL IMMUNOLOGY
- Systemic immune mechanisms in atopic dermatitis and psoriasis with implications for treatment
- (2017) Emma Guttman-Yassky et al. EXPERIMENTAL DERMATOLOGY
- JAK inhibition as a therapeutic strategy for immune and inflammatory diseases
- (2017) Daniella M. Schwartz et al. NATURE REVIEWS DRUG DISCOVERY
- Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
- (2017) Thomas Ruzicka et al. NEW ENGLAND JOURNAL OF MEDICINE
- Atopic dermatitis
- (2016) Stephan Weidinger et al. LANCET
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
- (2016) Eric L. Simpson et al. NEW ENGLAND JOURNAL OF MEDICINE
- The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-co
- (2015) O. Nemoto et al. BRITISH JOURNAL OF DERMATOLOGY
- RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications
- (2015) Mayte Suárez-Fariñas et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Association of Vitiligo and Alopecia Areata With Atopic Dermatitis
- (2015) Girish C. Mohan et al. JAMA Dermatology
- Suppression of Cytokine Signaling by SOCS3: Characterization of the Mode of Inhibition and the Basis of Its Specificity
- (2012) Jeffrey J. Babon et al. IMMUNITY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More